Information Provided By:
Fly News Breaks for February 20, 2020
Feb 20, 2020 | 07:49 EDT
Cowen analyst Boris Peaker noted Heron Therapeutics announced the FDA extended the review period for its NDA for HTX-011 by up to three months. The analyst feels the update is an incremental setback, but not changing the long-term outlook for HTX-011 in his model. Peaker reiterated his Outperform rating and $40 price target on Heron Therapeutics shares.
News For HRTX From the Last 2 Days
There are no results for your query HRTX